Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer, Lilly And Merck Strike Up Cancer Research Partnership In Asia

This article was originally published in The Pink Sheet Daily

Executive Summary

The not-for-profit Asian Cancer Research Group will focus initially on identifying biomarkers for lung and gastric cancers.

You may also be interested in...



Biomarkers For Alzheimer's, Parkinson's Disease To Be Developed By Industry Coalition Through First-Of-A-Kind Clinical Data Exchange

Unable to defeat Alzheimer's Disease and Parkinson's Disease, companies have joined forces to come up with new research tools

Big Pharma Stretches To Reshape Itself To Enter Asia With Flexible, Multiple-Partner Networks – Singapore Conference

SINGAPORE - As big pharma looks across Asia for new ways of doing business, execs from the top pharma companies agreed that having people on the ground in Asia is critical and that companies are moving away from being fully integrated pharma companies to becoming fully integrated pharma networks

Asian CROs On The March, But Tie-Ups Carry Risk: Analyst

SAN FRANCISCO - Pointing to the potential for a "perfect storm" in China and Asia with regard to contract research organizations' growth, Lehman Brothers analyst Douglas Tsao switched his metaphor to bolster the warning

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070267

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel